STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
Phase 1 Withdrawn
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Phase 1 Withdrawn
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Phase 1 Withdrawn
Study of OB-002 in Patients With Refractory Metastatic Cancer
Phase 1 Withdrawn
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
Phase 1 Withdrawn
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
Phase 1 Withdrawn
ProglumidePanc
Phase 1 Withdrawn
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
Phase 1 Withdrawn
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Phase 1 Withdrawn
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
Phase 1 Withdrawn
PanDox
Phase 1 Withdrawn
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Phase 1 Withdrawn
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Phase 1 Withdrawn
PANC-001
Phase 1 Withdrawn
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
Phase 1 Withdrawn
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
Phase 1 Withdrawn
The Role of Meat-borne Carcinogens in Pancreatic Cancer
Phase 1 Withdrawn
C-VISA BikDD: Liposome in Advanced Pancreatic Cancer
Phase 1 Withdrawn
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
Phase 1 Withdrawn
PCC
Phase 1 Withdrawn
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Phase 1 Withdrawn
GI-4000 With Adoptive Transfer in Pancreatic Cancer
Phase 1 Withdrawn
Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
Phase 1 Withdrawn
Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
Phase 1 Withdrawn
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Phase 1 Withdrawn
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
Phase 1 Withdrawn
Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
Phase 1 Withdrawn
Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer
Phase 1 Withdrawn
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer
Phase 1 Withdrawn